Concept explainers
Mary and Marcie. identical twins, go to the same internist who is also a faculty member at a major medical center. At their last visit, they each received a brochure describing a genetics research program recently launched by the hospital and its affiliated university. Researchers were asking for volunteers to fill out a questionnaire and a consent form, donate a blood sample, and have their medical records encoded and transferred to a database. The goal was to enroll 100,000 participants, and the brochure noted that over 10,000 people had already agreed to participate.
The blood sample would be used to extract DNA. which would be encoded with the same number as the medical records. This DNA would be used to search for genes associated with conditions such as arthritis, diabetes, and Alzheimer disease. The idea is that researchers interested in studying arthritis would use the medical records to identify which participants have the condition and then use DNA from those individuals to find genetic similarities that are not present in participants who do not have arthritis. The genetic similarities help identify regions of the genome that contain genes associated with arthritis. These regions can then be studied in detail to identify and isolate genes that may be associated with arthritis and other inflammatory disorders.
In exchange for enrolling, participants would be informed about any genetic conditions or predispositions to genetic disease they carry and would receive free access to testing. After discussing the brochure. Mary decided to enroll, but Marcie decided she did not want to do so. She said she did not want to know what diseases she may develop or which disease genes she may carry.
At their next annual visit. Mary’s internist told her that because her questionnaire indicated that some relatives had Alzheimer disease, her DNA was used in a study to identify risk genes. He said she had been identified as a carrier of a gene that greatly increased the likelihood that she would develop Alzheimer disease. The physician told her that age was the greatest risk factor, and while it was not 100% certain she would become a victim of Alzheimer disease, the gene she carries is a factor in 20–25% of all cases. Mary asked if there was anything she could do about these findings. The internist told her that exercise, controlling blood pressure and cholesterol levels, as well as participating in mentally challenging activities such as reading or playing a musical instrument may all help reduce her chances of developing this disease. Mary then asked if Marcie was going to be told about Mary’s genetic risk, and the internist said that he would not tell her.
For the next few days. Mary was conflicted about the situation. Marcie was an Identical twin, and If Mary carried a gene predisposing her to Alzheimer disease. Marcie must carry the same gene. Marcie did not exercise with Mary, had high blood pressure, and little interest in reading or social activities. Mary did not know whether she should tell Marcie.
If you were advising Mary, what would you say? Should she tell Marcie about the risk? Should she not tell her, but instead try to get Marcie to exercise and be more social? Should Mary ask their internist to talk with Marcie about this?
To explain: The suggestions an individual would give to Mary in the given situation.
Introduction: Alzheimer is a genetic disease that leads to permanent dementia (memory loss) in old ages. It is one of the most common forms of dementia in elderly people. Symptoms of Alzheimer disease are somewhat different from dementia caused due to other reasons. It is a genetic disorder that is caused by genetic mutations of some genes that are associated with human memory. These genetic mutations cause structural as well as cellular changes in the brain and its activities leading to reduced capability of memorizing things and effect on daily life activities.
Explanation of Solution
In the case as of the twin sisters Mary and Marcie, a person would suggest similar things that the physician suggested to Mary. She would be told to have a healthy body with regular exercise and balanced diet. For a person who is likely to become a patient of the known disease, it is very beneficial to adopt the habits that would delay or reduce the severity of the disease. For Alzheimer disease, it is very important to keep control of the blood pressure and the cholesterol level in the body.
Along with this, Mary would also be suggested to talk to her sister to get tested for the disease. Instead of taking the stress of the upcoming disease, it would be more beneficial to adopt the necessary measures that can reduce or delay the know disease.
To explain: Whether Mary should inform Marcie about the risk they both have or not.
Explanation of Solution
Upon getting to know about the risk of Alzheimer disease that both these twin sisters carry, Mary should definitely inform Marcie about it. She should make her aware of the upcoming disease and the possible ways for delaying and reducing the severity of the upcoming disease.
To explain: Whether Mary should not inform Marcie about the risk and try to get her to exercise and be more social.
Explanation of Solution
Although Mary should inform her sister Marcie about the risk of Alzheimer disease that she might be carrying, but she can also be motivated to be involved in more exercise and social activities. This can help her to delay the onset of the disease. Marcie can be made to understand the complete situation and helped in moving towards a healthier lifestyle.
To explain: Whether Mary should ask her internist to talk with Marcie about the situation or not.
Explanation of Solution
Mary can definitely ask her internist to talk to her sister Marcie regarding the genetic risk that Marcie would be carrying. She can ask the physician to make Marcie understand about the disease and the measures that can be adopted to delay the onset of the disease.
Want to see more full solutions like this?
Chapter 1 Solutions
Human Heredity: Principles and Issues
- Hi, I would like to know which program is used for the graphical presentation of the results of a meta-analysis of genome-wide linkage scans?arrow_forwardHuman Genome ProjectIn 2003, the Human Genome Project was successfully completed, determining the exact sequence of the entire human genome, which is made up of 3 billion nucleotide base pairs. The data generated from the Human Genome Project is freely available online to anyone. Many researches and innovations stemmed from the HGP, allowing the identifications of 1 800 disease genes. Many of the corporations using the results from the HGP are privately funded, and research is being done for profit even though the HGP results are provided freely.Identify one advantage and one disadvantage of corporate funding and patenting genetic research results.arrow_forwardGenetic application problems Two men (Father 1 and Father 2) claim in court the paternity of a child, whose blood group is 0. The mother is from group A, while the possible father 1 is from B and the possible father 2 is from AB. Please explain if this information can be used to indicate which of them is not your father. Come up with possible genotypes for the child, mother, and parents. Explain...arrow_forward
- Please verify if correct or not. If incorrect, please match descriptions with the correct mutation.arrow_forwardGenetics in Practice case studies are critical-thinking exercises that allow you to apply your new knowledge of human genetics to real-life problems. Case study Michelle was a 42-year-old woman who had declined counselling and amniocentesis at 16 weeks of pregnancy but was referred for genetic counseling after an abnormal ultrasound at 20 weeks of gestation. After the ultrasound, a number of findings suggested a possible chromosome abnormality in the fetus. The ultrasound showed swelling under the skin at the back of the fetuss neck; shortness of the femur, humerus, and ear length; and underdevelopment of the middle section of the fifth finger. Michelles physician performed an amniocentesis and referred her to the genetics program. Michelle and her husband did not want genetic counseling before receiving the results of the cytogenetic analysis. This was Michelles third pregnancy; she and her husband, Mike, had a 6-year-old daughter and a 3-year-old son. At their next session, the counselor informed the couple that the results revealed trisomy 21, explored their understanding of Down syndrome, and elicited their experiences with people with disabilities. She also reviewed the clinical concerns revealed by the ultrasound and associated anomalies (mild to severe intellectual disability, cardiac defects, and kidney problems). The options available to the couple were outlined. They were provided with a booklet written for parents making choices after the prenatal diagnosis of Down syndrome. After a week of careful deliberation with their family, friends, and clergy, they elected to terminate the pregnancy. Should physicians discourage a 42-year-old woman from having children because of an increased chance of a chromosomal abnormality?arrow_forwardGenetics in Practice case studies are critical-thinking exercises that allow you to apply your new knowledge of human genetics to real-life problems. Case study Michelle was a 42-year-old woman who had declined counselling and amniocentesis at 16 weeks of pregnancy but was referred for genetic counseling after an abnormal ultrasound at 20 weeks of gestation. After the ultrasound, a number of findings suggested a possible chromosome abnormality in the fetus. The ultrasound showed swelling under the skin at the back of the fetuss neck; shortness of the femur, humerus, and ear length; and underdevelopment of the middle section of the fifth finger. Michelles physician performed an amniocentesis and referred her to the genetics program. Michelle and her husband did not want genetic counseling before receiving the results of the cytogenetic analysis. This was Michelles third pregnancy; she and her husband, Mike, had a 6-year-old daughter and a 3-year-old son. At their next session, the counselor informed the couple that the results revealed trisomy 21, explored their understanding of Down syndrome, and elicited their experiences with people with disabilities. She also reviewed the clinical concerns revealed by the ultrasound and associated anomalies (mild to severe intellectual disability, cardiac defects, and kidney problems). The options available to the couple were outlined. They were provided with a booklet written for parents making choices after the prenatal diagnosis of Down syndrome. After a week of careful deliberation with their family, friends, and clergy, they elected to terminate the pregnancy. Do you think that this couple had the right to terminate the pregnancy in light of the prenatal diagnosis? If not, under what circumstance would a couple have this right? What other options were available to the couple?arrow_forward
- Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Should the physicians at UCLA have told Mr. Moore that his cells and its products were being commercially developed?arrow_forwardWho Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Do you think that donors or patients who provide cells and/or tissues should retain ownership of their body parts or should share in any financial benefits that might derive from their use in research or commercial applications?arrow_forwardExplain the relationship among the following terms: genomics, proteomics, gene, protein, genotype, and phenotype. minimum of 500 words please!arrow_forward
- True/False True or False? Transposon mutagenesis is useful for identifying essential genes in a cell. True or False? Transposons are found at various levels of complexity in bacteria. True or False? Transposons in eukaryotes are mechanistically different from bacterial transposons.arrow_forwardIf companies like 23 and me should be allowed to sequence your DNA and give you the results instead of making you discuss them with your Dr.arrow_forwardPlease answer fast Find a genetically modified organism of interest. What organism is the origin of the coding sequence? What is the product of this recombinant gene? What is the commercial interest in this GMO? What are the ethical concerns with GMOs?arrow_forward
- Human Heredity: Principles and Issues (MindTap Co...BiologyISBN:9781305251052Author:Michael CummingsPublisher:Cengage LearningBiology (MindTap Course List)BiologyISBN:9781337392938Author:Eldra Solomon, Charles Martin, Diana W. Martin, Linda R. BergPublisher:Cengage LearningBiology 2eBiologyISBN:9781947172517Author:Matthew Douglas, Jung Choi, Mary Ann ClarkPublisher:OpenStax